Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Arymo ER Approved, Parsabiv Returns, Merck Surprises With Keytruda Chemo Combo Submission

Jan 14 2017

• By Bridget Silverman

Related Content

Solidly Positive Phase III Data Boost Keryx’ Struggling Iron Drug Auryxia

Mar 29 2016

US FDA’s First Complete Response Letter Of 2017 Involves … Manufacturing

Jan 13 2017

Endo’s Opana ER, Generic Oxymorphone Safety Get US FDA Panel Review

Jan 11 2017

Egalet's Bid For Arymo ER Intranasal Abuse-Deterrence Claim Blocked By MorphaBond Exclusivity

Jan 11 2017

Amgen's Parsabiv's EU Approval Contrasts With US FDA Rejection

Nov 17 2016

It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer

Oct 25 2016

Game Changer: Merck's Stealth Keytruda-Chemo Filing Stirs NSCLC Market Dynamics

Jan 11 2017

Alexion’s Soliris Slips Up In Pivotal PROTECT Kidney Transplant Study

Dec 23 2016

Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market

May 19 2016

Related Companies

Merck & Co., Inc.

Genentech, Inc.

Amgen, Inc.

Tesaro, Inc.

Heron Therapeutics, Inc.

Alexion Pharmaceuticals Inc.

Keryx Biopharmaceuticals Inc.

Zyla Life Sciences

Endo, Inc.

Starpharma Holdings Limited

RedHill Biopharma Ltd.

Inspirion Delivery Technologies LLC

Daiichi Sankyo Co., Ltd.

Additional Topics

United States Approvals Complete Response Letters Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window